Logo

Qiagen Closes eGene Buy, Expects It to Contribute As Much As $9M in '08

Jul 10, 2007
NEW YORK (GenomeWeb News) — Qiagen said today that it has closed its $34 million acquisition of eGene, and said it expects the company to contribute strong revenue growth by next year.
  
Specifically, the company said it expects the acquisition to contribute $2 million in the second half of 2007 and between $7 million and $9 million for full year 2008.
 
The acquisition, originally announced April 12, gives Qiagen’s North American Holdings subsidiary eGene’s multi-channel sample-separation and -analysis technology, its HDA GT12 genetic analyzer, as well as a software-analysis package and consumable cartridges used by molecular diagnostics and research markets.
 
The total purchase price for Irvine, Calif.-based eGene includes $15.5 million in cash and one million common Qiagen shares priced at $17 apiece. Qiagen also absorbed around $1.5 million in liabilities.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.